Mark Holodniy

Summary

Country: USA

Publications

  1. pmc Immune biomarker differences and changes comparing HCV mono-infected, HIV/HCV co-infected, and HCV spontaneously cleared patients
    Lauren E Kushner
    Veterans Affairs Palo Alto Health Care System, Palo Alto, California, United States of America
    PLoS ONE 8:e60387. 2013
  2. pmc HIV infection in the elderly
    Nancy Nguyen
    University of the Pacific School of Pharmacy and Health Sciences, Stockton, CA, USA
    Clin Interv Aging 3:453-72. 2008
  3. doi request reprint Results from a large-scale epidemiologic look-back investigation of improperly reprocessed endoscopy equipment
    Mark Holodniy
    Office of Public Health, Department of Veterans Affairs, Washington, DC, USA
    Infect Control Hosp Epidemiol 33:649-56. 2012
  4. ncbi request reprint Oseltamivir for treatment and prophylaxis of influenza infection
    Patricia Schirmer
    Stanford University, VA Palo Alto Health Care System, Division of Infectious Diseases and Geographic Medicine, Palo Alto, CA 94304, USA
    Expert Opin Drug Saf 8:357-71. 2009
  5. ncbi request reprint HIV-1 load quantitation: a 17-year perspective
    Mark Holodniy
    AIDS Research Center, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA 94304, USA
    J Infect Dis 194:S38-44. 2006
  6. ncbi request reprint Prevention of shingles by varicella zoster virus vaccination
    Mark Holodniy
    VA Palo Alto Health Care System, 3801 Miranda Ave 132, Palo Alto, CA 94306, USA
    Expert Rev Vaccines 5:431-43. 2006
  7. pmc Prevalence of HIV infection among inpatients and outpatients in Department of Veterans Affairs health care systems: implications for screening programs for HIV
    Douglas K Owens
    VA Palo Alto Health Care System, Palo Alto, Calif, USA
    Am J Public Health 97:2173-8. 2007
  8. doi request reprint Effect of treatment interruption and intensification of antiretroviral therapy on health-related quality of life in patients with advanced HIV: a randomized, controlled trial
    Vilija R Joyce
    VA Palo Alto Health Care System, VA Cooperative Studies Program Coordinating Center, VA HSR and D Health Economics Resource Center, Menlo Park, California 94025, USA
    Med Decis Making 32:70-82. 2012
  9. pmc Cost-effectiveness of newer antiretroviral drugs in treatment-experienced patients with multidrug-resistant HIV disease
    Ahmed M Bayoumi
    Center for Research on Inner City Health, The Keenan Research Center in the Li Ka Shing Knowledge Institute, St Michael s Hospital, Toronto, Ontario, Canada Department of Medicine, University of Toronto, Toronto, Ontario, Canada Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada Division of General Internal Medicine, St Michael s Hospital, Toronto, Ontario, Canada VA Palo Alto Health Care System, VA Cooperative Studies Program Coordinating Center, VA HSR and D Health Economics Resource Center, Menlo Park, CA Center for Health Economics, University of York, York, United Kingdom Center for Health Evaluation and Outcome Sciences, St Paul s Hospital, Vancouver, British Columbia, Canada CIHR Canadian HIV Trials Network, Vancouver, British Columbia, Canada School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada VA Palo Alto Health Care System, Palo Alto, CA Department of Medicine, Stanford University, Stanford, CA Duke Clinical Research Institute, Duke University, Durham, Cancer Research UK
    J Acquir Immune Defic Syndr 64:382-91. 2013
  10. pmc Impact of interferon-ribavirin treatment on hepatitis C virus (HCV) protease quasispecies diversity in HIV- and HCV-coinfected patients
    Aarthi Chary
    AIDS Research Center, Veterans Affairs Palo Alto Health Care System, Palo Alto, California 94304, USA
    J Infect Dis 202:889-93. 2010

Detail Information

Publications64

  1. pmc Immune biomarker differences and changes comparing HCV mono-infected, HIV/HCV co-infected, and HCV spontaneously cleared patients
    Lauren E Kushner
    Veterans Affairs Palo Alto Health Care System, Palo Alto, California, United States of America
    PLoS ONE 8:e60387. 2013
    ..Few studies have evaluated HIV/HCV co-infection, and little longitudinal data exists describing a broader antiviral cytokine response...
  2. pmc HIV infection in the elderly
    Nancy Nguyen
    University of the Pacific School of Pharmacy and Health Sciences, Stockton, CA, USA
    Clin Interv Aging 3:453-72. 2008
    ..This article is intended for the general clinician, including geriatricians, and will review epidemiologic data and HIV treatment as well as provide a discussion on medical management issues affecting the older HIV-infected patient...
  3. doi request reprint Results from a large-scale epidemiologic look-back investigation of improperly reprocessed endoscopy equipment
    Mark Holodniy
    Office of Public Health, Department of Veterans Affairs, Washington, DC, USA
    Infect Control Hosp Epidemiol 33:649-56. 2012
    ..To determine whether improper high-level disinfection practices during endoscopy procedures resulted in bloodborne viral infection transmission...
  4. ncbi request reprint Oseltamivir for treatment and prophylaxis of influenza infection
    Patricia Schirmer
    Stanford University, VA Palo Alto Health Care System, Division of Infectious Diseases and Geographic Medicine, Palo Alto, CA 94304, USA
    Expert Opin Drug Saf 8:357-71. 2009
    ..Treatment and prophylaxis against influenza have been successful using antiviral medications such as adamantanes and neuraminidase inhibitors...
  5. ncbi request reprint HIV-1 load quantitation: a 17-year perspective
    Mark Holodniy
    AIDS Research Center, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA 94304, USA
    J Infect Dis 194:S38-44. 2006
    ....
  6. ncbi request reprint Prevention of shingles by varicella zoster virus vaccination
    Mark Holodniy
    VA Palo Alto Health Care System, 3801 Miranda Ave 132, Palo Alto, CA 94306, USA
    Expert Rev Vaccines 5:431-43. 2006
    ..Durability of vaccine response and possible booster vaccination will still need to be determined...
  7. pmc Prevalence of HIV infection among inpatients and outpatients in Department of Veterans Affairs health care systems: implications for screening programs for HIV
    Douglas K Owens
    VA Palo Alto Health Care System, Palo Alto, Calif, USA
    Am J Public Health 97:2173-8. 2007
    ..We sought to determine the prevalence of HIV in both inpatient and outpatient settings in 6 Department of Veterans Affairs (VA) health care sites...
  8. doi request reprint Effect of treatment interruption and intensification of antiretroviral therapy on health-related quality of life in patients with advanced HIV: a randomized, controlled trial
    Vilija R Joyce
    VA Palo Alto Health Care System, VA Cooperative Studies Program Coordinating Center, VA HSR and D Health Economics Resource Center, Menlo Park, California 94025, USA
    Med Decis Making 32:70-82. 2012
    ..The effect of antiretroviral therapy (ART) interruption or intensification on health-related quality of life (HRQoL) in advanced HIV patients is unknown...
  9. pmc Cost-effectiveness of newer antiretroviral drugs in treatment-experienced patients with multidrug-resistant HIV disease
    Ahmed M Bayoumi
    Center for Research on Inner City Health, The Keenan Research Center in the Li Ka Shing Knowledge Institute, St Michael s Hospital, Toronto, Ontario, Canada Department of Medicine, University of Toronto, Toronto, Ontario, Canada Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada Division of General Internal Medicine, St Michael s Hospital, Toronto, Ontario, Canada VA Palo Alto Health Care System, VA Cooperative Studies Program Coordinating Center, VA HSR and D Health Economics Resource Center, Menlo Park, CA Center for Health Economics, University of York, York, United Kingdom Center for Health Evaluation and Outcome Sciences, St Paul s Hospital, Vancouver, British Columbia, Canada CIHR Canadian HIV Trials Network, Vancouver, British Columbia, Canada School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada VA Palo Alto Health Care System, Palo Alto, CA Department of Medicine, Stanford University, Stanford, CA Duke Clinical Research Institute, Duke University, Durham, Cancer Research UK
    J Acquir Immune Defic Syndr 64:382-91. 2013
    ..Newer antiretroviral drugs provide substantial benefits but are expensive. The cost-effectiveness of using antiretroviral drugs in combination for patients with multidrug-resistant HIV disease was determined...
  10. pmc Impact of interferon-ribavirin treatment on hepatitis C virus (HCV) protease quasispecies diversity in HIV- and HCV-coinfected patients
    Aarthi Chary
    AIDS Research Center, Veterans Affairs Palo Alto Health Care System, Palo Alto, California 94304, USA
    J Infect Dis 202:889-93. 2010
    ..The effect of prior interferon-ribavirin treatment on HCV NS3 will likely not impact HCV PI efficacy in HIV-coinfected patients receiving ART...
  11. doi request reprint Determinants of the cost of health services used by veterans with HIV
    Paul G Barnett
    VA Health Economics Resource Center, 795 Willow Road, Menlo Park, CA, USA
    Med Care 49:848-56. 2011
    ..The effect of adherence, treatment failure, and comorbidities on the cost of HIV care is not well understood...
  12. doi request reprint Impact of highly active antiretroviral therapy on hepatitis C virus protease quasispecies diversity in HIV co-infected patients
    Mark A Winters
    AIDS Research Center, VA Palo Alto Health Care System, Palo Alto, California 94304, USA
    J Med Virol 82:791-8. 2010
    ..These results suggest ARV treatment for HIV would not affect the efficacy of HCV PI treatment...
  13. doi request reprint Quantitation of hepatitis C virus RNA in peripheral blood mononuclear cells in HCV-monoinfection and HIV/HCV-coinfection
    Aarthi Chary
    AIDS Research Center, VA Palo Alto Health Care System, Palo Alto, California, USA
    J Med Virol 84:431-7. 2012
    ..Differences in PBMC HCV viral load based on HIV-coinfection status and the significance of greater copy number in B-cells requires further study...
  14. pmc Cost effectiveness of screening strategies for early identification of HIV and HCV infection in injection drug users
    Lauren E Cipriano
    Department of Management Science and Engineering, Stanford University, Stanford, California, USA
    PLoS ONE 7:e45176. 2012
    ..To estimate the cost, effectiveness, and cost effectiveness of HIV and HCV screening of injection drug users (IDUs) in opioid replacement therapy (ORT)...
  15. pmc New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis
    Shan Liu
    Center for Health Policy, Stanford University, CA, USA
    Ann Intern Med 156:279-90. 2012
    ..Protease inhibitors increase the effectiveness of standard therapy, but they are costly. A genetic assay may identify patients most likely to benefit from this treatment advance...
  16. pmc Results of antiretroviral treatment interruption and intensification in advanced multi-drug resistant HIV infection from the OPTIMA trial
    Mark Holodniy
    VA Palo Alto Health Care System, Palo Alto, California, United States of America
    PLoS ONE 6:e14764. 2011
    ..Guidance is needed on best medical management for advanced HIV disease with multidrug resistance (MDR) and limited retreatment options. We assessed two novel antiretroviral (ARV) treatment approaches in this setting...
  17. pmc HIV testing of at risk patients in a large integrated health care system
    Douglas K Owens
    VA Palo Alto Healthcare System, Palo Alto, CA, USA
    J Gen Intern Med 22:315-20. 2007
    ..Understanding HIV screening practices and barriers to HIV testing is an important prelude to designing successful HIV screening programs. Our objective was to evaluate current practice patterns for identification of HIV...
  18. ncbi request reprint Connection domain mutations in treatment-experienced patients in the OPTIMA trial
    Birgitt Dau
    AIDS Research Center, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA 94304, USA
    J Acquir Immune Defic Syndr 54:160-6. 2010
    ....
  19. ncbi request reprint Recent advances in hepatitis C virus treatment: review of HCV protease inhibitor clinical trials
    Aarthi Chary
    VA Palo Alto Health Care System, Palo Alto, CA 94304, USA
    Rev Recent Clin Trials 5:158-73. 2010
    ..This review outlines the advances and the challenges in the development of these HCV PIs as effective HCV antiviral agents and their role in clinical practice...
  20. doi request reprint Interferon combination therapy for HIV/hepatitis C virus coinfection
    Aarthi Chary
    VA Palo Alto Health Care System, Palo Alto, CA, USA
    Immunotherapy 3:1087-102. 2011
    ..Understanding the basis of this population's poor response to interferon-based therapy is crucial to future exploration of new therapeutic options, immunotherapy and prognosis in HIV/HCV-coinfected population...
  21. ncbi request reprint High levels of adherence do not prevent accumulation of HIV drug resistance mutations
    David R Bangsberg
    Epidemiology and Prevention Interventions Center, Division of Infectious Diseases, San Francisco General Hospital, California, USA
    AIDS 17:1925-32. 2003
    ....
  22. ncbi request reprint A systematic review of cost-utility analyses in HIV/AIDS: implications for public policy
    John Hornberger
    The SPHERE Institute Acumen, LLC, Burlingame, California, USA
    Med Decis Making 27:789-821. 2007
    ..To determine whether gaps exist in published cost-utility analyses as measured by their coverage of topics addressed in current HIV guidelines from the Department of Health and Human Services (DHHS)...
  23. pmc Cost-effectiveness analysis of risk-factor guided and birth-cohort screening for chronic hepatitis C infection in the United States
    Shan Liu
    Department of Management Science and Engineering, Stanford University, Stanford, California, United States of America
    PLoS ONE 8:e58975. 2013
    ..We assessed one-time risk assessment and screening to identify previously undiagnosed 40-74 year-olds given newly available hepatitis C treatments...
  24. ncbi request reprint Frequency of HIV screening in the Veterans Health Administration: implications for early diagnosis of HIV infection
    Ronald O Valdiserri
    Department of Veterans Affairs, Public Health Strategic Health Care Group, Washington, DC 20420, USA
    AIDS Educ Prev 20:258-64. 2008
    ..We estimate that fewer than 10% of VA inpatients and fewer than 5% of VA outpatients were tested for HIV during the survey period. Substantial opportunities for increasing routine HIV testing exist in this population...
  25. doi request reprint Health-related quality of life in a randomized trial of antiretroviral therapy for advanced HIV disease
    Vilija R Joyce
    Veterans Affairs Palo Alto Health Care System, Veterans Affairs Cooperative Studies Program Coordinating Center, Menlo Park, CA 94025, USA
    J Acquir Immune Defic Syndr 50:27-36. 2009
    ..To assess and compare alternative approaches of measuring preference-based health-related quality of life (HRQoL) in treatment-experienced HIV patients and evaluate their association with health status and clinical variables...
  26. pmc Hepatitis C virus protease gene diversity in patients coinfected with human immunodeficiency virus
    Mark A Winters
    Division of Infectious Diseases and Geographic Medicine, Stanford University, California, USA
    J Virol 80:4196-9. 2006
    ..01). Significant variability exists within HCV protease gene variants at the patient level and could affect the effectiveness of HCV protease inhibitors...
  27. pmc Risk of cardiovascular disease from antiretroviral therapy for HIV: a systematic review
    Clay Bavinger
    Center for Primary Care and Outcomes Research, and Center for Health Policy, Stanford University, Stanford, California, United States of America
    PLoS ONE 8:e59551. 2013
    ..Recent studies suggest certain antiretroviral therapy (ART) drugs are associated with increases in cardiovascular disease...
  28. doi request reprint Comparative assessment of antimicrobial usage measures in the Department of Veterans Affairs
    Patricia L Schirmer
    Office of Public Health, Department of Veterans Affairs, Palo Alto, California, USA
    Infect Control Hosp Epidemiol 33:409-11. 2012
    ..The number of grams used calculated from BCMA data provided the most informative antimicrobial utilization measure...
  29. ncbi request reprint Darunavir in the treatment of HIV-1 infection: a viewpoint by Mark Holodniy
    Mark Holodniy
    AIDS Research Center, Department of Medicine, Stanford University, Palo Alto, California, USA
    Drugs 67:2803. 2007
  30. ncbi request reprint The effect of diagnosis with HIV infection on health-related quality of Life
    Shyoko Honiden
    VA Palo Alto Health Care System 111A, 3801 Miranda Avenue, Palo Alto, CA
    Qual Life Res 15:69-82. 2006
    ..Years after diagnosis, although half of the patients believed that diagnosis reduced health-related quality of life, one-third reported improved health-related quality of life...
  31. ncbi request reprint Utilization and access to antiretroviral genotypic resistance testing and results within the US Department of Veterans Affairs
    Matthew Bidwell Goetz
    Infectious Diseases Section, Department of Medicine, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA 90073, USA
    J Acquir Immune Defic Syndr 41:59-62. 2006
    ..We sought to characterize variation in the use of HIV genotypic resistance tests and how results were reported...
  32. doi request reprint Integrating tobacco cessation into mental health care for posttraumatic stress disorder: a randomized controlled trial
    Miles McFall
    Veterans Affairs Puget Sound Health Care System, 1660 S Columbian Way, S 116 MHC, Seattle, WA 98108, USA
    JAMA 304:2485-93. 2010
    ..Most smokers with mental illness do not receive tobacco cessation treatment...
  33. pmc Impact of highly active antiretroviral therapy and immunologic status on hepatitis C virus quasispecies diversity in human immunodeficiency virus/hepatitis C virus-coinfected patients
    Jennifer M Babik
    Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, California 94305, USA
    J Virol 77:1940-50. 2003
    ..These results suggest that there is no immediate effect of HAART on HCV but that, with prolonged HAART, immune restoration results in an increase in HCV load and quasispecies diversity...
  34. doi request reprint Clinically significant drug interactions in younger and older human immunodeficiency virus-positive patients receiving antiretroviral therapy
    Pannyun Yiu
    Pharmacy Service, Veterans Affairs Palo Alto Health Care System, Palo Alto, California 94304, USA
    Pharmacotherapy 31:480-9. 2011
    ..To characterize clinically significant drug interactions (CSDIs) in younger and older human immunodeficiency virus (HIV)-positive patients who were receiving antiretroviral therapy...
  35. pmc Development of elvitegravir resistance and linkage of integrase inhibitor mutations with protease and reverse transcriptase resistance mutations
    Mark A Winters
    AIDS Research Center, Veterans Affairs Palo Alto Health Care System, Palo Alto, California, United States of America
    PLoS ONE 7:e40514. 2012
    ..Continued appearance of new INI DRMs after initial INI failure suggests a potent, highly dynamic selection of INI resistant strains that is unaffected by co-location with PI and RTI DRMs...
  36. pmc Public health practice is not research
    Jean Lin Otto
    Jean Lin Otto is with the Henry M Jackson Foundation for the Advancement of Military Medicine, contracted to work at the Armed Forces Health Surveillance Center, Silver Spring, MD Mark Holodniy is with the Office of Public Health, Department of Veterans Affairs, Washington, DC Robert F DeFraites is with the Uniformed Services University of the Health Sciences, Bethesda, MD
    Am J Public Health 104:596-602. 2014
    ....
  37. pmc Pharmacokinetics and tolerability of oseltamivir combined with probenecid
    Mark Holodniy
    US Department of Veterans Affairs, Office of Public Health and Environmental Hazards, Washington, DC, USA
    Antimicrob Agents Chemother 52:3013-21. 2008
    ..012). Alternate-day dosing of oseltamivir plus dosing with probenecid four times daily achieved trough oseltamivir carboxylate concentrations adequate for neuraminidase inhibition in vitro, and this combination should be studied further...
  38. pmc Dengue surveillance in Veterans Affairs healthcare facilities, 2007-2010
    Patricia L Schirmer
    Office of Public Health, Department of Veterans Affairs, Palo Alto, California, USA
    PLoS Negl Trop Dis 7:e2040. 2013
    ....
  39. ncbi request reprint Infectious complications in OIF/OEF veterans with traumatic brain injury
    Birgitt Dau
    Department of Veterans Affairs VA, Palo Alto Health Care System, Palo Alto, CA 94304, USA
    J Rehabil Res Dev 46:673-84. 2009
    ..In this review, providers will become more familiar with the scope and complexity of infectious disease management in veterans with TBI...
  40. pmc Effective detection of the 2009 H1N1 influenza pandemic in U.S. Veterans Affairs medical centers using a national electronic biosurveillance system
    Patricia Schirmer
    Office of Public Health Surveillance and Research, Department of Veterans Affairs, Palo Alto, California, United States of America
    PLoS ONE 5:e9533. 2010
    ..We also describe trends noted in influenza-like illness (ILI) outpatient encounter data in VA medical centers during the 2008-09 influenza season, before and after the recognition of pandemic H1N1 2009 influenza virus...
  41. pmc Enhanced health event detection and influenza surveillance using a joint Veterans Affairs and Department of Defense biosurveillance application
    Cynthia A Lucero
    Department of Veterans Affairs, Office of Public Health, Office of Public Health Surveillance and Research, Palo Alto, CA 94304, USA
    BMC Med Inform Decis Mak 11:56. 2011
    ..The goal of this study was to evaluate disease surveillance using a biosurveillance application which combined data from both populations...
  42. doi request reprint Novel targets for antiretroviral therapy: clinical progress to date
    Birgitt Dau
    VA Palo Alto Health Care System, Palo Alto, California, USA
    Drugs 69:31-50. 2009
    ..A number of other drug targets, such as CCR5 co-receptor agonists, CXCR4 co-receptor antagonists, novel fusion inhibitors, and alternative antiretroviral strategies, such as immune stimulation and gene therapy, are under investigation...
  43. doi request reprint GBV-C viremia and clinical events in advanced HIV infection
    Harleen Sahni
    VA Palo Alto HCS, Palo Alto, California
    J Med Virol 86:426-32. 2014
    ..GBV-C co-infection in multidrug-resistant HIV infected patients was associated with a trend in improved survival but not decreased AIDS events. Analysis was limited by cohort size...
  44. ncbi request reprint Health-related quality of life assessment after antiretroviral therapy: a review of the literature
    Harleen Gakhar
    Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, CA, USA
    Drugs 73:651-72. 2013
    ....
  45. pmc Case files from Stanford University Medical Center: the initial presentation of HIV-1 infection--where public and personal health meet
    Minghsun Liu
    Division of Infectious Diseases, Stanford University Medical Center, Stanford, California, USA
    MedGenMed 8:24. 2006
  46. ncbi request reprint Proteomic analysis of serum cytokine levels in response to highly active antiretroviral therapy (HAART)
    Karen I Relucio
    Divison of Infectious Diseases and Geographic Medicine, Stanford University, Stanford, California, USA
    J Proteome Res 4:227-31. 2005
    ..Protein microarrays are useful for initial screening of novel cytokine expression. Further studies are needed to elucidate the role of MIG and IP-10 in response to HAART...
  47. ncbi request reprint Relationship between antiretroviral prescribing patterns and treatment guidelines in treatment-naive HIV-1-infected US veterans (1992-2004)
    Mark Holodniy
    AIDS Research Center, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA 94340, USA
    J Acquir Immune Defic Syndr 44:20-9. 2007
    ..To analyze temporal patterns of antiretroviral (ARV) prescribing practices relative to nationally defined guidelines in treatment-naive patients with HIV-1 infection...
  48. pmc Ultrasensitive detection of rare mutations using next-generation targeted resequencing
    Patrick Flaherty
    Stanford Genome Technology Center, Stanford University, Palo Alto, CA 94304, USA
    Nucleic Acids Res 40:e2. 2012
    ..As a clinical application of this method, we analyzed nine clinical samples of H1N1 influenza A and detected an oseltamivir (antiviral therapy) resistance mutation in the H1N1 neuraminidase gene at a sample fraction of 0.18%...
  49. ncbi request reprint Representational fluency in HIV clinical practice: a model of instructor discourse
    Mary A Banach
    Stroke Sciences Group and the Clinical and Translational Science Institute, University of California San Francisco, San Francisco, CA, USA
    J Contin Educ Health Prof 27:149-56. 2007
    ..Little is known about instructor-participant discourse in HIV CME programs and whether or how instructors model their decision-making strategies...
  50. pmc The Relationship Between HIV Infection and Cardiovascular Disease
    Birgitt Dau
    VA Palo Alto Health Care System and Division of Infectious Diseases and Geographic Medicine, Stanford University, Palo Alto, CA, USA
    Curr Cardiol Rev 4:203-18. 2008
    ..We first review basic principles of HIV pathogenesis and treatment and then discuss relevant clinical management strategies that will be useful for cardiologists who might be involved in the care of HIV infected patients...
  51. pmc Maternal-fetal pharmacokinetics and dynamics of a single intrapartum dose of maraviroc in rhesus macaques
    Mark A Winters
    AIDS Research Center, VA Palo Alto Health Care System, Palo Alto, California 94304, USA
    Antimicrob Agents Chemother 54:4059-63. 2010
    ..The low concentrations of fetal maraviroc and short pharmacokinetic profile in infants suggest that a single maternal intrapartum dose of maraviroc would not be effective in reducing the risk of MTCT of HIV...
  52. ncbi request reprint Is spinal tuberculosis contagious?
    Patricia Schirmer
    VA Palo Alto Health Care System, Palo Alto, CA 94304, USA
    Int J Infect Dis 14:e659-66. 2010
    ....
  53. doi request reprint Use of dried clinical samples for storing and detecting influenza RNA
    Mark Winters
    VA Palo Alto Health Care System, Palo Alto, CA, USA
    Influenza Other Respir Viruses 5:413-7. 2011
    ....
  54. ncbi request reprint Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy
    Gillian D Sanders
    Duke Clinical Research Institute, Duke University, Durham, NC 27715, USA
    N Engl J Med 352:570-85. 2005
    ..The costs, benefits, and cost-effectiveness of screening for human immunodeficiency virus (HIV) in health care settings during the era of highly active antiretroviral therapy (HAART) have not been determined...
  55. pmc Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4
    Theresa L Y Chang
    Osel, Inc, 1800 Wyatt Drive, Suite 14, Santa Clara, CA 95054, USA
    Proc Natl Acad Sci U S A 100:11672-7. 2003
    ..This represents an important first step toward the development of engineered commensal bacteria within the vaginal microflora to inhibit heterosexual transmission of HIV...
  56. ncbi request reprint Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation: an international comparison (The GUESS Study)
    Andrew R Zolopa
    Stanford University School of Medicine, Stanford, CA 94305 5107, USA
    Clin Infect Dis 41:92-9. 2005
    ..We sought to determine how much agreement exists within a group of experts in the interpretation of complex genotypes...
  57. pmc Accuracy of the TRUGENE HIV-1 genotyping kit
    Robert M Grant
    Gladstone Institute of Virology and Immunology, San Francisco, CA 94141, USA
    J Clin Microbiol 41:1586-93. 2003
    ..This integrated assay system for the detection of HIV-1 drug resistance mutations has a high degree of accuracy and reproducibility in several laboratories...
  58. ncbi request reprint The safety and tolerability of Z-100 in patients infected with HIV-1
    Michael Borucki
    University of Texas, Tyler, TX, USA
    Antivir Ther 11:297-303. 2006
    ..Consequently, this trial demonstrates the safety of Z-100 in HIV-1 infected patients without evidence of any activity at the doses administered...
  59. ncbi request reprint HIV-1 RNA and viral load
    Karen Relucio
    Clin Lab Med 22:593-610. 2002
    ..There is now a better understanding of their limitations and the clinical scenarios and assay performance issues that result in variations of viral load results...
  60. ncbi request reprint Evolution of genotypic resistance algorithms and their impact on the interpretation of clinical trials: an OPTIMA trial substudy
    Samit Desai
    Department of Internal Medicine, Section of Infectious Diseases, Yale University School of Medicine, VA Connecticut Healthcare System, New Haven, Connecticut, USA
    HIV Clin Trials 8:293-302. 2007
    ..This study was designed to determine how often these incorrect resistance interpretations affect analyses of long-term clinical trials, antiretroviral (ARV) choices, and HIV disease progression rates...
  61. pmc Cost-effectiveness of HIV screening in patients older than 55 years of age
    Gillian D Sanders
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    Ann Intern Med 148:889-903. 2008
    ..Recent guidelines recommend HIV screening in patients age 13 to 64 years. The cost-effectiveness of HIV screening in patients age 55 to 75 years is uncertain...
  62. pmc Multicenter evaluation of the performance characteristics of the bayer VERSANT HCV RNA 3.0 assay (bDNA)
    Tarek Elbeik
    Department of Laboratory Medicine, University of California, San Francisco 94110, USA
    J Clin Microbiol 42:563-9. 2004
    ..1%), a fold change of 2.6. Thus, the observed fold change between any two consecutive HCV RNA measures is expected to be less than 2.6-fold (equivalent to 0.41 log(10) IU/ml) 95% of the time in clinically stable individuals...
  63. ncbi request reprint An open-label randomized clinical trial of novel therapeutic strategies for HIV-infected patients in whom antiretroviral therapy has failed: rationale and design of the OPTIMA Trial
    Tassos C Kyriakides
    VA Cooperative Studies Program Coordinating Center, West Haven, Connecticut 06516, USA
    Control Clin Trials 24:481-500. 2003
    ..We discuss the rationale behind the OPTIMA Trial design as well as the issues arising from the conduct of a trial that involves three national clinical trial agencies...
  64. doi request reprint Safety, tolerability, pharmacokinetics, and efficacy of an interleukin-2 agonist among HIV-infected patients receiving highly active antiretroviral therapy
    Richard T Davey
    National Institutes of Health, National Institute of Allergy and Infectious Disease, Bethesda, MD 20892, USA
    J Interferon Cytokine Res 28:89-100. 2008
    ..Bay 50-4798 was generally well tolerated across the dose range tested, but a lack of potent, sustained immunologic activity suggests that further optimization of dose and schedule will be necessary...